Top

Reactions Weekly

Published in:

01-02-2020 | Anaphylaxis | Case report

Alectinib/cisplatin

Various toxicities: case report

Published in: Reactions Weekly | Issue 1/2020

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Nakai R, et al. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin. Clinical Case Reports 7: 2500-2504, No. 12, Dec 2019. Available from: URL: http://doi.org/10.1002/ccr3.2543 CrossRef

Title: Alectinib/cisplatin
Various toxicities: case report
Publication date: 01-02-2020
Publisher: Springer International Publishing
Keywords: Anaphylaxis
Anaphylaxis
Alectinib
Brentuximab vedotin
Published in: Reactions Weekly / Issue 1/2020
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-75125-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Alectinib/cisplatin

Various toxicities: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Risperidone

Filgrastim/Lenograstim

Cytarabine/daunorubicin/midostaurin

Isotretinoin/testosterone

Prednisone

Heparin/warfarin